Opportunity Information: Apply for RFA GM 10 002
Apply for RFA GM 10 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pharmacogenomics Knowledge Base, PharmGKB (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on Mar 5, 2009 and posted on Mar 5, 2009.
- Applicants must submit their applications by Jun 2, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pharmacogenomics Knowledge Base, PharmGKB (R24) opportunity (Funding Opportunity Number RFA-GM-10-002) is a National Institute of General Medical Sciences (NIGMS), NIH grant meant to support either new or renewal efforts to operate and further develop PharmGKB (www.pharmgkb.org), which the announcement notes will be renamed the Pharmacogenomics Knowledge Base. The core purpose is to maintain and advance a community-wide knowledge resource for pharmacogenomics, rather than a database tailored to a single consortium or project. In practical terms, NIGMS is funding the continued build-out of an informatics and curation platform that can serve as the central place where researchers and other stakeholders can find, interpret, and reuse high-value pharmacogenomics knowledge.
The announcement emphasizes that PharmGKB is expected to be complete, comprehensive, and current, meaning it should capture the breadth of pharmacogenomics knowledge and keep pace with ongoing discoveries. It is not just a list of findings; it should be supported by critical datasets (even if those datasets are stored in other archival repositories) and grounded in the most compelling peer-reviewed literature. In other words, the knowledge base should function as a carefully curated, evidence-linked resource that makes it easier for users to understand relationships among genes, genetic variation, drugs, and drug response phenotypes, while still pointing back to the underlying evidence sources that justify those relationships.
A central theme of the opportunity is the informatics challenge of integrating large and disparate information types. Pharmacogenomics evidence comes in many forms, such as genotype-phenotype associations, functional variant data, clinical outcome observations, dosing guidelines, pathway and mechanism knowledge, and results spanning multiple experimental and clinical contexts. NIGMS highlights that a compelling resource must manage these heterogeneous data streams in a way that is organized, consistent, and easy to use. Usability is treated as a major requirement: the end product should be extremely valuable to the people trying to advance the field and to those working to implement pharmacogenomics in real-world settings.
The ultimate goal described in the opportunity is aligned with the overarching goal of pharmacogenomics itself: guiding appropriate therapeutic choices. PharmGKB is expected to support and extend modern research approaches that move the field toward clinically meaningful decision-making, such as selecting drugs, adjusting doses, reducing adverse drug reactions, and improving treatment outcomes by accounting for genetic and genomic factors. The announcement frames the knowledge base as infrastructure that accelerates both research progress and translation, by making reliable, well-structured knowledge easier to find and apply.
The funding context also matters: PharmGKB previously sat within the Pharmacogenetics Research Network (PGRN), but NIGMS separated the knowledge base into its own R24 mechanism so it can clearly serve the entire pharmacogenomics community, independent of any single network. The PGRN itself is referenced as being supported under a different funding opportunity (RFA-GM-10-001). This separation signals that PharmGKB is intended to be a broadly shared, field-wide platform, not merely an internal resource for a network.
Administratively, this is a discretionary grant in the health funding activity category, with CFDA number 93.859 (Biomedical Research and Research Training), and it does not require cost sharing or matching. Eligible applicants span a wide range of organizations, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities outside higher education), small businesses, and other for-profit organizations. The posting and creation date are March 5, 2009, with an original and current closing date of June 2, 2009, and an archive date of July 3, 2009. For official details, NIH points applicants to the full announcement link (http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-10-002.html) and provides NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
Frequently Asked Questions (FAQs)
What is the PharmGKB (R24) funding opportunity?
It is an NIGMS, NIH discretionary grant opportunity (Funding Opportunity Number RFA-GM-10-002) intended to support either a new award or a renewal effort to operate and further develop PharmGKB (www.pharmgkb.org), which the announcement notes will be renamed the Pharmacogenomics Knowledge Base.
Which NIH institute is sponsoring this opportunity?
The opportunity is sponsored by the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH).
What is the main purpose of the grant?
The core purpose is to maintain and advance a community-wide knowledge resource for pharmacogenomics, rather than a database tailored to a single consortium or project. The funded work is expected to continue building an informatics and curation platform that serves as a central place to find, interpret, and reuse high-value pharmacogenomics knowledge.
Is the goal to build a database for a specific consortium or project?
No. The announcement emphasizes that PharmGKB is meant to serve the entire pharmacogenomics community and should not be tailored to a single consortium, network, or project.
What does NIGMS expect PharmGKB to be like (scope and quality)?
The announcement describes the resource as expected to be complete, comprehensive, and current. It should capture the breadth of pharmacogenomics knowledge and keep pace with ongoing discoveries.
What kinds of content should the knowledge base include?
The opportunity highlights that pharmacogenomics evidence spans multiple information types, including genotype-phenotype associations, functional variant data, clinical outcome observations, dosing guidelines, pathway and mechanism knowledge, and results across multiple experimental and clinical contexts.
Does PharmGKB need to be supported by peer-reviewed literature?
Yes. The announcement indicates the knowledge base should be grounded in the most compelling peer-reviewed literature and function as a curated, evidence-linked resource that points back to underlying evidence sources.
Does the opportunity require hosting all datasets inside PharmGKB?
No. The announcement notes that PharmGKB should be supported by critical datasets even if those datasets are stored in other archival repositories, while still linking back to those evidence sources.
Why does the announcement emphasize informatics and integration?
A central theme is the informatics challenge of integrating large and disparate information types. NIGMS highlights the need to manage heterogeneous pharmacogenomics data streams in an organized, consistent, and easy-to-use way.
How important is usability in this opportunity?
Usability is treated as a major requirement. The end product is expected to be extremely valuable to users advancing pharmacogenomics research as well as stakeholders working to implement pharmacogenomics in real-world settings.
What is the ultimate goal PharmGKB is meant to support?
The announcement ties the knowledge base to the overarching goal of pharmacogenomics: guiding appropriate therapeutic choices. It is expected to support approaches that enable clinically meaningful decision-making, such as selecting drugs, adjusting doses, reducing adverse drug reactions, and improving outcomes by accounting for genetic and genomic factors.
How does this opportunity relate to the Pharmacogenetics Research Network (PGRN)?
PharmGKB previously sat within the PGRN, but NIGMS separated the knowledge base into its own R24 mechanism so it can clearly serve the entire pharmacogenomics community, independent of any single network.
Is the PGRN funded under this same announcement?
No. The PGRN is referenced as being supported under a different funding opportunity (RFA-GM-10-001), while PharmGKB is supported under RFA-GM-10-002.
What type of grant mechanism is used for this opportunity?
The announcement describes this as an R24 mechanism focused on supporting the operation and further development of the Pharmacogenomics Knowledge Base (PharmGKB).
What is the CFDA number for this grant?
The CFDA number listed is 93.859 (Biomedical Research and Research Training).
What is the funding activity category?
The opportunity is listed under the health funding activity category.
Is cost sharing or matching required?
No. The announcement states that cost sharing or matching is not required.
Who is eligible to apply?
Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities outside higher education), small businesses, and other for-profit organizations.
When was this opportunity posted?
The posting and creation date is March 5, 2009.
What is the application closing date?
The original and current closing date listed is June 2, 2009.
When was the opportunity archived?
The archive date is July 3, 2009.
Where can applicants find the official full announcement?
The announcement link provided is http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-10-002.html.
Who should be contacted for access or linking issues with the announcement?
The opportunity notes that NIH provides NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
Browse more opportunities from the same category: Health
Next opportunity: Family Centered Substance Abuse Treatment Grants for Adolescents and their Families
Previous opportunity: Clean Cities FY 09 Petroleum Reduction TechnologiesProjects for Transportation Sector
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA GM 10 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA GM 10 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Family Centered Substance Abuse Treatment Grants for Adolescents and their Families Apply for TI 09 002 Funding Number: TI 09 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Addressing Emerging Infectious Diseases and Related Public Health Threats in the Peoples Republic of China (U01) Apply for RFA GH09 002 Funding Number: RFA GH09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Phased Innovation Award Program for AIDS Vaccine Research (R21/R33) Apply for PA 09 119 Funding Number: PA 09 119 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Public Health Traineeship Apply for HRSA 09 201 Funding Number: HRSA 09 201 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Novel Interventions for Neurodevelopmental Disorders (R34) Apply for RFA MH 09 160 Funding Number: RFA MH 09 160 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Novel Interventions for Neurodevelopmental Disorders (R21/R33) Apply for RFA MH 09 161 Funding Number: RFA MH 09 161 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| International Collaborations in Infectious Disease Research (ICIDR) (U01) Apply for RFA AI 09 010 Funding Number: RFA AI 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Addressing Asthma from a Public Health Perspective Apply for CDC RFA EH09 901 Funding Number: CDC RFA EH09 901 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $950,000 |
| 2009 FPH Region 2 (Virgin Islands) Apply for PA FPH 09 002 Funding Number: PA FPH 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $853,000 |
| Prematurity and Respiratory Outcomes Program (PROP) (U01) Apply for RFA HL 10 007 Funding Number: RFA HL 10 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Sudden Unexpected Infant Death Case Registry A Pilot Study Apply for CDC RFA DP09 904 Funding Number: CDC RFA DP09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $130,000 |
| SPRANS Cooperative Agreement Programs Health Insurance Financing for Children with Special Health Apply for HRSA 09 137 Funding Number: HRSA 09 137 Agency: Health Resources and Services Administration Category: Health Funding Amount: $550,000 |
| Capacity Building Assistance (CBA) to Improve the Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) Prevention Services for High Risk and/or Racial/Ethnic Minority Populations Apply for CDC RFA PS09 906 Funding Number: CDC RFA PS09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,462,500 |
| Department of Defense HIV/AIDS Prevention, Care and Treatment Program Apply for DHAPPBAA09 002 Funding Number: DHAPPBAA09 002 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| Alcohol Research Resource Awards (R24) Apply for PAR 09 128 Funding Number: PAR 09 128 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Probe Production Centers Network (MLPCN) (R03) Apply for PAR 09 129 Funding Number: PAR 09 129 Agency: National Institutes of Health Category: Health Funding Amount: $25,000 |
| Exploratory Investigations in Food Allergy (R21) Apply for RFA AI 09 011 Funding Number: RFA AI 09 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Dental Reimbursement Program Apply for HRSA 09 133 Funding Number: HRSA 09 133 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Telehealth Resource Center Grant Program Apply for HRSA 09 195 Funding Number: HRSA 09 195 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Statewide Consumer Network Grant Apply for SM 09 014 Funding Number: SM 09 014 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $70,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA GM 10 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.